Document |
Document Title |
WO/2024/048899A1 |
The present invention relates to a pharmaceutical composition for alleviating or treating sequelae of cerebral infarction, comprising glia-like cells differentiated from a human mesenchymal stem cell (hMSC). The pharmaceutical compositio...
|
WO/2024/047527A1 |
Disclosed herein are compositions, kits, and methods for preventing, ameliorating, or treating chemotherapy-induced peripheral neuropathy (CIPN) and/or reducing the severity of one or more risk factors, signs, or symptoms associated with...
|
WO/2024/050527A2 |
The present disclosure provides intranasal compositions of a dihydropyridine compound, and methods of using said compositions for the treatment of one or more conditions.
|
WO/2024/046223A1 |
The present application relates to substituted indazole formamide derivatives, a preparation method therefor, and the use of a pharmaceutical composition containing the derivatives or deuterated derivatives in medicines. Specifically, th...
|
WO/2024/050478A1 |
Provided herein are chimeric receptors comprising an amyloid-reactive peptide, as well as cells comprising the chimeric receptors. Also provided herein are methods of treating amyloid-based diseases by administering a cell comprising a c...
|
WO/2024/046837A1 |
The present disclosure relates to tryptamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-H...
|
WO/2024/050001A1 |
Described is a polypeptide including the intracellular domain of CX3CL1 (CX3CL1- ICD), including an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 and pharmaceutical compositions including the above-described polypept...
|
WO/2024/046922A1 |
The present invention relates to a new composition comprising hydrolysed alpha-s1-casein and a fish protein hydrolysate, to the method for producing said composition and to the use of the composition in a food supplement, in solid or liq...
|
WO/2024/050026A2 |
Disclosed herein is a method of treating chronic and acute neuroinflammatory symptoms of a CNS disorder by administration of effective amounts of sublytic concentrations of a cholesterol dependent cytolysin (CDC).
|
WO/2024/044847A1 |
The present application relates to methods of activating serotonin receptors in a cell using indoline derivatives of general Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, as well as to treating diseas...
|
WO/2024/048519A1 |
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...
|
WO/2024/046393A1 |
Provided is a method for trans-differentiating non-neuronal cells of a mammal into neurons. The method comprises: providing a negative regulator capable of reducing the expression of negative regulatory genes, the negative regulatory gen...
|
WO/2024/048900A1 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular dementia comprising glia-like cells differentiated from human mesenchymal stem cells (hMSC). The pharmaceutical composition of the present ...
|
WO/2024/046279A1 |
The present invention relates to a compound of formula (I), which has a plurality of crystal forms. The crystal forms of the compound show good stability in addition to higher purity, especially crystal form I, crystal form II and crysta...
|
WO/2024/049976A1 |
The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined in the specification. The compounds may be radiolabeled compounds and are useful for diagnosti...
|
WO/2024/046277A1 |
Disclosed in the present invention are a series of nitrogen-containing bridged heterocyclic compounds and a preparation method therefor, and particularly a compound represented by formula (I) and a pharmaceutically acceptable salt thereo...
|
WO/2024/049275A1 |
The present invention relates to a novel benfotiamine choline salt, a preparation method thereof, and a use thereof. A benfotiamine choline salt according to the present invention has excellent stability and significantly higher water so...
|
WO/2024/049236A1 |
The present invention relates to: a method for preparing a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof by using a chiral organocatalytic compound; and a composition for preventing, alleviating or treating...
|
WO/2024/050323A1 |
Provided are antidepressant therapies, methods for augmenting antidepressant therapies, particularly antidepressant therapies that have failed to produce an adequate response, and to patient populations who benefit from such augmentation.
|
WO/2024/048782A1 |
The disclosure relates generally to methods of treating central nervous system disorders using (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane (i.e. centanafadine) or a pharmaceutically acceptable salt thereof. More particularly, t...
|
WO/2024/046504A1 |
The present disclosure relates to an EP300/CBP regulator as shown in formula I, and a preparation method therefor and the use thereof. The structure of formula I is as follows.
|
WO/2024/044848A1 |
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
WO/2024/046361A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or conditions related to the activity of RIPK1 kinase.
|
WO/2024/042526A1 |
Disclosed are cannabis compositions including cannflavin at or above a predetermined minimal concentration for a consistent therapeutic effect, and methods of using the same, for treating sleep difficulties, pain, headaches, abdominal pa...
|
WO/2024/041460A1 |
The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...
|
WO/2024/042466A1 |
Polypeptides that traverse the blood-brain-barrier (BBB) are disclosed. The peptide can serve as BBB-traversing transport vehicles for delivering active agents from the circulation into across the BBB to contact cells and tissues within ...
|
WO/2024/043298A1 |
The present invention addresses the problem of increasing the abundances of bacteria belonging to the genera Parabacteroides and Bifidobacterium in intestinal bacterial flora. Provided is a composition for improving intestinal bacterial ...
|
WO/2024/043975A1 |
The present invention provides novel compositions and methods for inducing and/or activating regulatory T cells (Treg). Wherein a method of treating, inhibiting, and/or preventing a disease or disorder in a subject in need thereof, said ...
|
WO/2024/040935A1 |
Provided is use of a sacubitril/valsartan substance in the preparation of a drug for treating drug addiction and relapse. The sacubitril/ valsartan substance comprises at least one of a sacubitril monomer, a sacubitril derivative, a phar...
|
WO/2024/044469A1 |
Provided herein are compositions and methods for treatment of Amyotrophic Lateral Sclerosis as well as Spinocerebellar Ataxia Type 2 by way of reducing levels of the ATXN2 gene expression. More specifically, miRNA compositions that targe...
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
WO/2024/044179A1 |
Analgesic compounds which bind to multiple opioid receptors are provided, e.g., they bind to both the mu opioid receptor (MOR) and the kappa opioid receptor (KOR). The compounds are effective in relieving pain without causing addiction, ...
|
WO/2024/043114A1 |
Disclosed is a composition that promotes expression of integrin α5. The composition comprises shell ginger leaf extract.
|
WO/2024/042250A1 |
Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).
|
WO/2024/043260A1 |
The present invention relates to a pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane (centanafadine) or a pharmaceutically acceptable salt thereof as an active ingredient, and a formulation compr...
|
WO/2024/042147A2 |
The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R4 and X1 are as defined above, composition including the compounds and methods of using the compounds.
|
WO/2024/041596A1 |
Disclosed in the present application is use of phenytoin sodium as a mitophagy inducer. Provided in the present application is new use of the phenytoin sodium as the mitophagy inducer, which can selectively induce damaged mitochondria to...
|
WO/2024/044760A1 |
Formulations of dendrimer conjugated to one or more antidepressant or antipsychotic agents, having greater selectivity of targeting to cell types and decreased risk of side effects, and methods of use thereof, have been developed. Prefer...
|
WO/2024/042523A1 |
The present disclosure concerns formulations for oral delivery of at least one active agent of a compound according to formula (I) and/or (II) for the treatment of glycogen storage diseases, neurodegenerative disorders and autophagy-rela...
|
WO/2024/044344A1 |
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/044756A1 |
Dendrimer formulations including one or more psychedelic or hallucinogenic agents, and methods of use thereof are described. Preferably, the dendrimer-conjugated agents selectively bind to one or more receptors on the surface or inside t...
|
WO/2024/042480A1 |
The present invention relates to heteroaromatic compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as antagonist at serotonin 5-HT2A receptor and agonist at serotonin 5-HT1A rec...
|
WO/2024/043809A1 |
The invention relates to the field of pharmaceuticals and concerns pharmaceutical compositions containing gabapentin, as well as dosage forms based on gabapentin, and methods for producing and using said compositions and dosage forms, wh...
|
WO/2024/042226A2 |
A method for producing a purified morphinan-glycoside conjugate. The method includes the steps of contacting a morphinan compound with an activated saccharide or activated oligosaccharide and a glycosyltransferase in a reaction mixture u...
|
WO/2024/044730A1 |
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/042494A1 |
The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...
|
WO/2024/044574A1 |
The present disclosure provides methods for reducing ionizing radiation-induced damage of cells such as hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The methods comprise introducing into HSCs and/or HPCs a f...
|
WO/2024/041385A1 |
Provided is use of Cs4-SeNPs in preparing a product for resisting neurodegeneration diseases such as Parkinson's disease.
|
WO/2024/044151A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors, to treat a receptor-interacting protein kinase 1-mediated disease or...
|